Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 25 of the 34 sources its claims cite were checked for support.

Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials

Open access
Greff, Dorina, Juhász, Anna E., Váncsa, Szilárd, Váradi, Alex, Sipos, Zoltán, Szinte, Julia, Park, Sunjune, Hegyi, Péter, Nyirády, Péter, Ács, Nándor, Várbíró, Szabolcs, Horváth, Eszter M. · 2023 · Reproductive Biology and Endocrinology

Abstract

Background: Metformin is the gold standard insulin sensitizer, which is widely used to treat insulin resistance in polycystic ovary syndrome (PCOS). However, metformin may induce gastrointestinal side effects. Objective: Inositols have long been debated as a potential alternative for metformin in treating PCOS. Therefore, the present systematic review aimed to evaluate the efficacy and safety of inositols in treating PCOS. Methods: The present systematic search was performed in CENTRAL, MEDLINE, and Embase from the inception until October 20th, 2021. Eligible randomized controlled trials (RCTs) included women diagnosed with PCOS and compared any inositols with metformin or placebo. Our primary outcome was cycle normalization, whereas secondary outcomes were body mass index (BMI), parameters of carbohydrate metabolism and clinical and laboratory hyperandrogenism. Results are reported as risk ratios or mean differences (MDs) with 95% confidence intervals (CIs). Results: Twenty-six RCTs were identified, including data of 1691 patients (806 inositol, 311 with placebo, and 509 metformin groups). In patients treated with inositols, the risk (CI: 1.13; 2.85) of having a regular menstrual cycle was found by 1.79 higher than in the case of placebo. Moreover, the inositols showed non-inferiority compared to metformin in this outcome. In the case of BMI (MD = -0.45; CI: -0.89; -0.02), free testosterone (MD = -0,41, CI: -0.69; -0.13), total testosterone (MD = -20.39, CI: -40.12; -0.66), androstenedione (MD = -0.69, CI: -1,16; -0.22), glucose (MD = -3.14; CI: -5.75; -0.54) levels and AUC insulin (MD = -2081.05, CI: -2745.32; -1416.78) inositol treatment induced greater decrease compared to placebo. Inositol increased sex-hormone-binding globulin significantly compared to placebo (MD = 32.06, CI:1.27; 62.85). Conclusion: Inositol is an effective and safe treatment in PCOS. Moreover, inositols showed non-inferiority in most outcomes compared to the gold standard treatment; metformin. Trial registration: PROSPERO registration number: CRD42021283275.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 26 RCTs found that inositols improve menstrual cycle normalization, BMI, androgen levels, and some glycemic parameters in women with PCOS compared with placebo, with non-inferiority to metformin in most outcomes. Inositols also had fewer side effects than metformin.

Key findings

  • Inositol increased cycle normalization versus placebo (RR = 1.79, 95% CI 1.13–2.85) and was non-inferior to metformin (RR = 1.42, 95% CI 0.80–2.53).
  • Versus placebo, inositols reduced BMI (MD = −0.45 kg/m², 95% CI −0.89 to −0.02), free testosterone (MD = −0.41 ng/dl, 95% CI −0.69 to −0.13), total testosterone (MD = −20.39 ng/dl, 95% CI −40.12 to −0.66), androstenedione (MD = −0.69 ng/ml, 95% CI −1.16 to −0.22), glucose (MD = −3.14 mg/dl, 95% CI −5.75 to −0.54), and AUC insulin (MD = −2081.05 μU/ml/min, 95% CI −2745.32 to −1416.78), while increasing SHBG (MD = 32.06 nmol/L, 95% CI 1.27–62.85).
  • Four studies comparing inositol with metformin reported a lower side-effect rate in the inositol group (7% vs 53%; RR = 0.16, 95% CI 0.09–0.28); metformin side effects included bloating, nausea, and generalized weakness.
  • The authors report that inositols were non-inferior to metformin for most outcomes, including total testosterone, glycemic parameters, BMI, and cycle normalization.

Methods

  • Systematic review and meta-analysis following PRISMA 2020 and the Cochrane Handbook, registered on PROSPERO (CRD42021283275).
  • Searched CENTRAL, MEDLINE, and Embase from inception until October 20, 2021, for RCTs of women with PCOS comparing any inositol with metformin or placebo.
  • Included 26 RCTs with 1691 women (806 inositol, 311 placebo, 509 metformin); 24 studies were included in the quantitative synthesis. Pooled risk ratios or mean differences with 95% CIs used random-effects models; heterogeneity assessed with I² and Cochran Q; GRADE used for quality of evidence.

Limitations

  • The paper states limitations including small number of studies with small sample sizes, heterogeneous populations, differing follow-up times, different inositol dosages and monotherapy versus combinations, problematic generalization of pregnancy-rate results because only one study analyzed women who wanted pregnancy, missing AUC-insulin and glucose graphs, and moderate-to-high risk of bias in some domains.
  • The text also makes evident that the primary outcome was changed from ovulation and menstrual cycle length to menstrual cycle normalization because of lack of data, and the minimum number of studies for meta-analysis was decreased to two.
  • The paper notes that cycle normalization data were heterogeneous and that pregnancy outcome definitions were heterogeneous, carrying a significant risk of bias.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12958-023-01055-z

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 PRISMA 2020 flowchart representing the study selection process
Fig. 1 PRISMA 2020 flowchart representing the study selection processCC BY · PubMed Central
Fig. 2 Forest plots representing the risk of cycle normalization in the groups treated with inositols compared to placebo or metformin
Fig. 2 Forest plots representing the risk of cycle normalization in the groups treated with inositols compared to placebo or metforminCC BY · PubMed Central

Verification

Claims the paper makes

16 Valid · 3 Not valid · 6 Not checked · 97 Own results and interpretations

74 more claims · 3 with their cited sources checked

Create a free account to see all 122 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 29
  • It may state two separate claims as one. 24

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

2 of 2

Citations

Cites

2 retracted

Show all 51 references

Research works printed but not linked: 4

  1. Nehra J, Kaushal J, Singhal SR, Ghalaut VS. A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women. Int J Pharm Sci Res. 2017;8(4):1664–70.
  2. Higgins JPT LT, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane. 2022. https://training.cochrane.org/handbook/current/chapter-06.
  3. Schünemann H. The GRADE handbook: Cochrane Collaboration. 2013.
  4. Schillaci R, Mangione D, Lo Monte G, Vassiliadis A. Inositol supplementation and IVF outcome: Preliminary data. Italian J Gynaecol Obstetr. 2012;24(1):38–44.

Cited by

See all 143

Metadata

Authors
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., Várbíró, S., & Horváth, E. M.
Affiliations
  • Semmelweis University (HU)
  • University of Pecs (HU)
Venue
Reproductive Biology and Endocrinology
Published
2023-01-26
Volume
21
Issue
1
Pages
10-10
ISSN
1477-7827 (ISSN-L)
OpenAlex
W4318054803
Cited by
143
References
51
Citations by year
2026: 35 · 2025: 51 · 2024: 41 · 2023: 16
FWCI
5.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Reproductive Biology and Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Research, Development, and Innovation Office (NKFIH-FK129206)
  • Semmelweis University
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
polycystic ovary syndrome, myo-inositol, metformin, insulin resistance, body mass index, hyperandrogenism, sex hormone-binding globulin, insulin sensitivity, glucose metabolism, treatment safety, insulin sensitizers, androstenedione, free testosterone, sex hormones
MeSH terms
Female, Humans, Hypoglycemic Agents, Inositol, Metformin, Polycystic Ovary Syndrome, Testosterone, Randomized Controlled Trials as Topic, Insulins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1186/s12958-023-01055-z
The paper
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., Várbíró, S., & Horváth, E. M. (2023). Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology. https://doi.org/10.1186/s12958-023-01055-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.